Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.55 |
| ▸ | ITGA2 | P17301 | 7/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | MMP7 | P09237 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13700378 | 0.82 | ITGB1 (0.72) | ITGB1ITGA2ITGA4MMP9MMP2 | |
| SCHEMBL8245234 | 0.82 | ITGB1 (0.66) | ITGB1ITGA2ITGA4MMP9MMP1 | |
| SCHEMBL4259018 | 0.82 | ITGB1 (0.66) | ITGB1ITGA2ITGA4MMP9MMP1 | |
| SCHEMBL8248993 | 0.80 | ITGB1 (0.70) | ITGB1ITGA2ITGA4MMP9MMP1 | |
| SCHEMBL8246799 | 0.79 | MCL1 (0.39) | ITGB1ITGA2ITGA4ATMMCL1 | |
| SCHEMBL12084795 | 0.79 | ITGB1 (0.71) | ITGB1ITGA2ITGA4MMP1MMP2 | |
| SCHEMBL4249877 | 0.79 | ITGB1 (0.71) | ITGB1ITGA2ITGA4MMP1MMP2 | |
| SCHEMBL8245644 | 0.75 | ITGB1 (0.64) | ITGB1ITGA2ITGA4MMP9MMP2 | |
| SCHEMBL1487410 | 0.74 | ITGB1 (0.75) | ITGB1ITGA2ITGA4MMP9MMP2 | |
| SCHEMBL13700636 | 0.73 | ITGB1 (0.39) | ITGB1ITGA2ITGA4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | ITGB1 4/4885ITGA2 3/4885ITGA4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.